Global engineering technologies company, Renishaw, is pleased to announce that its award-winning neuroinfuse™ drug delivery device, the only platform currently to allow for repeated, intermitent infusions into the the parenchyma, has continued to safely and effectively deliver infusions as part of an extension to a first-in-human clinical trial of cerebral dopamine neurotrophic factor (CDNF).
Global engineering technologies company, Renishaw, announces that its award-winning intraparenchymal drug delivery device, has played a critical role in a joint Phase 1-2 clinical study with Herantis Pharma plc, for the investigation of cerebral dopamine
projít na článekLab2Clinic™ CNS drug delivery service is an innovative concept which leverages Renishaw’s extensive experience in neurological drug delivery to accelerate the drug development timeline, aiding translation from research to clinical trials.
projít na článekDiffuse intrinsic pontine glioma (DIPG) is a rare but deadly brain tumour. No child has ever survived it, most becoming paralysed and dying in just a few months. Now an novel investigational drug delivery system, which delivers therapeutic agents directly
projít na článekIntraparenchymal drug delivery offers a practical method of bypassing the blood-brain barrier (BBB) and shows great promise in providing the next step change in the treatment of neurodegenerative, neuro oncology and other debilitating neurological conditi
projít na článekThe University of California, Los Angeles (UCLA), USA, combines Raman microscopy with scanning electron microscopy (SEM) to study archaeological textiles and fibres. UCLA use a Renishaw SEM-SCA system to study textiles and fibres, non-destructively. The f
projít na článek